+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 52 Actively Recruiting clinical trials

A

Actively Recruiting

Researchers are conducting a master protocol study called IIBD to evaluate the safety and effectiveness of new treatments for adults with moderately to severely active ulcerative colitis or Crohns disease. This phase 2, randomized, controlled study includes multiple individual sub-studies that share key design features. Participants are assigned to the appropriate sub-study before being randomized to a treatment group, with the overall study lasting at least 62 weeks. The study treatments include mirikizumab given intravenously IV during the first study period. Responders then receive mirikizumab subcutaneously SC in the second period. Another group will receive oral LY4395089 combined with IV mirikizumab initially, then responders stop LY4395089 and continue with mirikizumab SC. These two treatment approaches are being assessed in parallel groups. Participants will undergo screening to confirm diagnosis and disease activity, followed by regular study visits during the treatment periods. Researchers will monitor laboratory test results and evaluate response to treatment using measures such as the modified Mayo score for ulcerative colitis and the Crohns disease activity index. The primary outcome includes tracking the number of participants assigned to each treatment group up to day 42. The study runs through March 2028 with ongoing safety and efficacy assessments.

Age: 18Years - 80YearsAll GendersPhase 2
71 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of Datopotamab Deruxtecan Dato-DXd with or without durvalumab compared to chemotherapy chosen by doctors combined with pembrolizumab in people with PD-L1 positive locally recurrent inoperable or metastatic triple-negative breast cancer TNBC. This Phase III international study aims to see if Dato-DXd plus durvalumab can help patients live longer without their cancer worsening or improve overall survival, while also assessing impacts on quality of life. Participants are randomly assigned to one of three groups Dato-DXd with durvalumab, a chemotherapy option paclitaxel, nab-paclitaxel, or gemcitabine plus carboplatin combined with pembrolizumab, or Dato-DXd alone. All study drugs are given by intravenous infusion. The study will monitor patients for disease progression and response, with treatments and evaluations continuing for up to about 33 months. During the study, participants will undergo regular assessments including tumor measurements by imaging using RECIST 1.1 criteria, survival tracking, and quality of life evaluations focused on symptoms like breast and arm pain and physical functioning. Safety and drug effects will also be closely monitored throughout treatment and follow-up. The total study participation may last several years, with some outcomes measured up to 64 months from randomization.

Age: 18Years +All GendersPhase 3
318 locations
O

Actively Recruiting

Researchers are conducting a noninterventional, prospective observational study in Canada to monitor participants with Alzheimers Disease who are treated with LEQEMBI during routine clinical practice. The study aims to describe the occurrence and severity of known side effects, including brain imaging abnormalities and intracerebral hemorrhages, and analyze these according to genetic factors, other medications, and baseline brain scans. Additionally, the study will observe the progression of Alzheimers Disease and identify any previously unknown side effects related to LEQEMBI. Participants in this registry study are those prescribed LEQEMBI and will be observed without any experimental treatment or intervention. The study collects data on drug use, adverse events, disease progression, and the effectiveness of safety measures over a period of up to three years. There is no active treatment administered by the study, and information is gathered during routine medical care. During the study, participants will have their health monitored through regular clinical practice assessments. Researchers will track side effects, disease progression, treatment duration, and drug utilization. Data on serious adverse reactions, treatment discontinuations, and deaths within 30 days of stopping LEQEMBI will also be collected. The study will last up to three years with ongoing observation to evaluate the safety and outcomes associated with LEQEMBI use.

All AgesAll Genders
17 locations
R

Actively Recruiting

Researchers are evaluating radiation treatments for women with small, node-negative invasive breast cancer measuring 3 cm or less. This trial compares partial breast irradiation PBI to whole breast irradiation WBI, both given once daily over about one week after breast-conserving surgery. The main goal is to see if PBI is not worse than WBI for preventing local cancer recurrence and if it improves cosmetic outcomes, as judged by patients, three years after treatment. Participants are randomly assigned to receive either PBI or WBI. Both groups receive a total radiation dose of 26 Gy split into five daily treatments over 5 to 7 days, with a possible extension to 8 days due to scheduling. The WBI targets the entire breast, while PBI focuses radiation on the tumor bed plus a margin of normal tissue. Patients are not informed which treatment they receive to avoid bias in assessing cosmetic results. Key factors such as tumor size, estrogen receptor status, and treatment center are used for group assignment. During the study, participants will be monitored annually for five years to assess local recurrence, distant disease-free survival, overall survival, and radiation side effects. Cosmetic outcomes will be evaluated by both patients and clinical staff at 3 and 5 years. Quality of life will also be measured at multiple time points. The study lasts several years, with primary outcomes assessed at three years and continued follow-up through at least five years post-treatment.

Age: 50Years - 120YearsFEMALEPhase 3
31 locations
C

Actively Recruiting

Researchers are evaluating camizestrant compared to standard endocrine therapy in patients with ER-positive, HER2-negative early breast cancer who have an intermediate or high risk of disease recurrence. This Phase III open-label study includes patients who have completed definitive locoregional therapy, with or without chemotherapy, and have received standard adjuvant endocrine therapy for at least 2 years and up to 5 years. The study aims to determine if camizestrant improves invasive breast cancer-free survival and other important outcomes over a long-term follow-up. Participants will be randomly assigned to receive either camizestrant orally or continue standard endocrine therapy chosen by their doctor, which may include aromatase inhibitors like exemestane, letrozole, anastrozole, or tamoxifen. Treatment in both groups will last for up to 60 months. The study allows prior use of CDK46 inhibitors and includes an open-label design where both participants and researchers know the assigned treatment. During the study, participants will be monitored with assessments including survival outcomes, disease-free survival, relapse-free survival, and overall survival for up to 10 years from the last patient randomized. Safety will be tracked through adverse event reporting, laboratory and vital signs tests, and symptom questionnaires measuring arthralgia, hot flushes, vaginal dryness, and quality of life. Pharmacokinetics will be studied up to 6 months after treatment starts. The total duration of participation can extend over many years to capture long-term results.

Age: 18Years - 130YearsAll GendersPhase 3
709 locations
A

Actively Recruiting

Researchers are evaluating the effect of LY3457263 compared with placebo on hemoglobin A1c HbA1c levels in adults with type 2 diabetes who have not reached their HbA1c goals despite stable treatment with semaglutide or tirzepatide. This phase 2, double-blind study aims to better understand how LY3457263 impacts blood sugar control in this population. Participants will receive once-weekly subcutaneous injections of either LY3457263 at one of three doses or a placebo, while continuing their stable dose of semaglutide or tirzepatide. The treatment period lasts 24 weeks, during which participants blood sugar and body weight changes will be monitored. The study includes a randomized, parallel-group design comparing these interventions. During the approximately 9-month study, participants will undergo assessments including measurements of HbA1c, fasting serum glucose, and body weight at baseline and week 24. Researchers will monitor safety and treatment effects throughout the study. Participants will have scheduled visits for treatment administration and evaluation, with the primary focus on HbA1c change from baseline at 24 weeks.

Age: 18Years - 75YearsAll GendersPhase 2
60 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a drug called LY4395089, a farnesoid X receptor FXR agonist, when given together with mirikizumab compared to mirikizumab alone in adults with moderately to severely active Crohns disease. This Phase 2 study is part of the IIBD master protocol and is expected to last about 62 weeks. The goal is to better understand how this combination treatment works for this condition. Participants will be assigned to one of two groups one receiving only mirikizumab and the other receiving both LY4395089 orally and mirikizumab intravenously during the first study period. Responders will then stop LY4395089 and receive mirikizumab subcutaneously in the second study period. Mirikizumab is given first via IV and later by a subcutaneous injection. The study compares these treatment approaches to assess differences in response. During the study, participants will undergo assessments including endoscopic evaluation to measure response up to week 12, clinical remission checks, and fecal calprotectin tests to monitor inflammation levels. Researchers will track safety and efficacy throughout the approximately 62-week study duration. Participants will have regular visits for treatment administration and monitoring, with the main focus on the percentage of participants achieving endoscopic response by week 12.

Age: 18Years - 80YearsAll GendersPhase 2
71 locations
C

Actively Recruiting

This trial is designed to evaluate the safety, tolerability, and effectiveness of the combination of nemtabrutinib plus venetoclax compared to venetoclax plus rituximab in adults with relapsed or refractory chronic lymphocytic leukemiasmall lymphocytic lymphoma RR CLLSLL. The study aims to confirm the dose of nemtabrutinib and assess progression-free survival as the primary outcome, using established criteria and independent review. Participants are assigned to one of two treatment groups. One group receives daily oral nemtabrutinib starting on the first day of cycle 1 and venetoclax starting on the first day of cycle 2, continuing up to two years or until disease progression or discontinuation. The other group receives daily oral venetoclax starting on cycle 1 day 1, plus intravenous rituximab infusion for six cycles. Each treatment cycle lasts four weeks. During the study, participants undergo regular monitoring for dose-limiting toxicities, adverse events, and treatment discontinuations. Assessments include progression-free survival, minimal residual disease in bone marrow, overall survival, response rates, and duration of response. The study duration spans several years, with safety and efficacy monitored throughout and follow-up extending beyond treatment completion to gather comprehensive data on participant outcomes.

Age: 18Years +All GendersPhase 3
99 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of tacabrutideg compared with investigators choice treatments in people with chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL who have previously been treated with both Bruton Tyrosine Kinase inhibitors BTKi and B-cell LeukemiaLymphoma 2 protein inhibitors BCL2i. This study aims to compare how long participants live without their disease worsening under these treatments. The study is a Phase 3, randomized trial sponsored by BeOne Medicines. Participants will be randomly assigned to receive either tacabrutideg taken orally once daily until treatment discontinuation criteria are met, or investigators choice of treatment. The investigators choice includes combinations such as idelalisib plus rituximab for CLL only, bendamustine plus rituximab, or venetoclax plus rituximab retreatment. Some of these drugs are administered orally while others are given intravenously. During the study, participants will be closely monitored for progression-free survival over approximately 36 months, along with overall survival and response rates. Researchers will assess quality of life using specific questionnaires for up to 24 months, and track treatment-emergent adverse events. The study involves regular assessments and evaluations to understand treatment effects and safety over the course of participation, which may last several years until study completion in 2030.

Age: 18Years +All GendersPhase 3
132 locations
G

Actively Recruiting

Non-small cell lung cancer NSCLC is a disease where cancer cells grow uncontrollably in lung tissues. This trial evaluates whether the investigational drug telisotuzumab vedotin works better than docetaxel and assesses its safety in adults with previously treated NSCLC that overexpresses c-Met. The study is a Phase 3 randomized trial involving about 768 participants worldwide to compare disease activity and side effects of these treatments. Participants will be randomly assigned to receive either telisotuzumab vedotin every two weeks or docetaxel every three weeks, both given as intravenous infusions. Treatment continues until specific discontinuation criteria are met. Those who benefit may have the option to continue treatment through an extension or rollover study. The study aims to compare how these two treatments affect disease progression and survival. During the study, participants will have regular hospital or clinic visits for medical assessments, blood tests, side effect monitoring, and questionnaires. Researchers will measure progression-free survival and overall survival up to about 39 months, along with response rates and quality of life indicators. The study includes detailed safety monitoring and may involve a higher treatment burden than standard care.

Age: 18Years +All GendersPhase 3
317 locations

1-10 of 52

1